Dabigatran etexilate mesylate: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
ShiSheng (talk | contribs)
nocaptcha
8,707 edits
Created page with "{{DrugProjectFormSinglePage |authorTag=SS |genericName=Dabigatran etexilate mesylate |aOrAn=an |drugClass=Anti-coagulant |indication=reduce the risk of stroke and systemic emb..."
 
Gerald Chi (talk | contribs)
CMEAdmin, Bureaucrats, bureaucrats, editnews, exportpages, interwiki, nocaptcha, nukepages, smwadministrator, Administrators, Widget editors
17,702 edits
m ←Redirected page to Dabigatran
 
(9 intermediate revisions by 2 users not shown)
Line 1: Line 1:
{{DrugProjectFormSinglePage
#REDIRECT [[Dabigatran]]
|authorTag=SS
|genericName=Dabigatran etexilate mesylate
|aOrAn=an
|drugClass=Anti-coagulant
|indication=reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation
|hasBlackBoxWarning=Yes
|adverseReactions=Esophagitis, Gastritis, Gastroesophageal reflux disease, Gastrointestinal hemorrhage Gastrointestinal ulcer, Indigestion, Bleeding
|blackBoxWarningTitle=DISCONTINUING PRADAXA IN PATIENTS  WITHOUT ADEQUATE CONTINUOUS ANTICOAGULATION INCREASES RISK OF STROKE
|blackBoxWarningBody=<i><span style="color:#FF0000;">Condition Name:</span></i> (iscontinuing PRADAXA places patients at an increased risk of thrombotic events. If anticoagulation with PRADAXA must be discontinued for a reason other than pathological bleeding, consider coverage with another anticoagulant.)
|fdaLIADAdult=&lt;h4&gt;Condition 1&lt;/h5&gt;
 
* Dosing Information
 
:: (Dosage)
}}

Latest revision as of 15:53, 28 March 2014

Redirect to:

Retrieved from "https://www.wikidoc.org/index.php?title=Dabigatran_etexilate_mesylate&oldid=960862"